Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation

Human Reproduction

Volumn 17, Issue 2, 2002, Pages 304-309

  Harlin, Jonas ^a   Aanesen, A ^a   Csemiczky, G ^a   Wramsby, H ^a   Fried, G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Delivery rates; Ovarian stimulation; Recombinant FSH

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; NOSE SPRAY; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELIVERY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG SYNTHESIS; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; OVARY FOLLICLE DEVELOPMENT; OVULATION INDUCTION; PREGNANCY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 0036178822     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/17.2.304     Document Type: Article

References (20)

1. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Recombinant Human FSH Study Group
2. What are the clinical benefits of recombinant gonadotrophins? Clinical efficacy of recombinant gonadotrophins
3. What are the clinical benefits of recombinant gonadotrophins? Recombinant follicle stimulating hormone
4. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F®) versus highly purified urinary FSH (Metrodin HP): Results of a randomized comparative study in women undergoing assisted reproductive techniques
5. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer
6. Optimal use of infertility diagnostic tests and treatments. The ESHRE Capri Workshop Group
7. Ovarian function in relation to the outcome of in vitro fertilization (IVF) treatment in regularly menstruating women with tubal infertility
8. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction
9. Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens
10. Recombinant follicle stimulating hormone in in-vitro fertilization treatment - Clinical experience with follitropin alpha and follitropin beta
11. The age-related decline in female fecundity: A quantitative controlled study of implanting capacity and survival of individual embryos after in vitro fertilization
12. Clinical experience with recombinant human FSH (Gonal-F®): A collaborative study in IVF/ET
13. Female reproductive aging - Ovarian and uterine factors
14. Success rate with repeated cycles of in vitro fertilization-embryo transfer
15. Age-related decline in female fertility is not due to diminished capacity of the uterus to sustain embryo implantation
16. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon® versus Metrodin®) in in-vitro fertilization
17. Recombinant follicle-stimulating hormone (follitropin beta, Puregon®) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins
18. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon®) in women undergoing ovarian stimulation
19. An analysis of the effect of age on implantation rates
20. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: A randomized clinical study